Ignite Creation Date:
2025-12-24 @ 10:59 PM
Ignite Modification Date:
2026-04-22 @ 7:43 PM
Study NCT ID:
NCT00301769
Status:
TERMINATED
Last Update Posted:
2013-09-30
First Post:
2006-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | View |
| None | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | View |
| None | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | View |
| None | Blastic Phase Chronic Myelogenous Leukemia | View |
| None | de Novo Myelodysplastic Syndromes | View |
| None | Previously Treated Myelodysplastic Syndromes | View |
| None | Recurrent Adult Acute Lymphoblastic Leukemia | View |
| None | Recurrent Adult Acute Myeloid Leukemia | View |
| None | Refractory Chronic Lymphocytic Leukemia | View |
| None | Relapsing Chronic Myelogenous Leukemia | View |
| None | Secondary Acute Myeloid Leukemia | View |
| None | Secondary Myelodysplastic Syndromes | View |
Keywords: